Description: Imugene Limited is an immuno-oncology focused biopharmaceutical company. The Company is engaged in the research and development of human epidermal growth factor receptor 2 positive (HER2 +ve), and gastric and breast cancer vaccines. The Company is also engaged in the research, development and commercialization of health technologies. HER-Vaxx is a cancer immunotherapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has completed a Phase I clinical trial with over 10 HER-2 positive patients with metastatic breast cancer. It was shown in pre-clinical studies and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu. HER-Vaxx has stimulated the production of HER-2 antibodies in early-stage cancer patients enrolled in the initial clinical trial. The Company is also developing mimotope-based immunotherapies against validated and oncology targets.
Home Page: www.imugene.com
IMU Technical Analysis
Transamerica Funds
,
Phone:
888-233-4339
Officers
| Name | Title |
|---|---|
| Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD | Exec. Chairman |
| Ms. Leslie Chong | CEO, MD & Exec. Director |
| Dr. Nicholas J. Ede B.Sc.(Hons.), Ph.D. | Chief Technology Officer |
| Dr. Monil Shah M.B.A., Pharm.D. | Chief Bus. Officer |
| Mr. Michael Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICD | Chief Financial Officer |
| Ms. Ursula McCurry | Sr. VP of Clinical Operations |
| Dr. Giovanni Selvaggi | Chief Medical Officer |
| Mr. Nathan Jong C.A. | Joint Company Sec. |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 8.5651 |
| Price-to-Sales TTM: | 81.6957 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |